Market barriers affect nearly 20% of myeloma prescriptions. Is your brand losing market share?
We surveyed 150 European oncologists and haematologists to find out how market barriers affect the way they prescribe 8 myeloma drugs. The results show that half of those treatments lose market share overall while the other half make small net gains.
Find out why, and learn what your brand can do to regain lost share, in Market Access Impact: Myeloma (EU5).
The report covers major brands from Amgen, BMS/AbbVie, Celgene, Johnson & Johnson, and Novartis. You’ll discover which brands see the biggest gains and losses from 7 different market barriers, which barriers help and hurt your brand the most, and which competitors you take share from and lose it to.
Half of brands are widely prescribed: Around 70% or more of the doctors surveyed prescribe 4 of the 8 brands covered. Over 90% of doctors prescribe the top brand.
Half of the surveyed brands gain share: The four most prescribed brands all see small barrier-related net increases, but the most prescribed brand gains nearly twice as much as any other.
The top barrier affects two brands disproportionately: Significantly more doctors experience this barrier with two of the least prescribed brands.
“Other” brands also gain: They take share from all of the surveyed brands, and in aggregate, see the third-largest net share gain.
Eliminating barriers would affect the middle of the market: Two middle-ranking brands would switch places, and the aggregate of “other” brands would move down the rankings.
Market access affects more prescriptions than other barriers: Taken together barriers related to market access drive a third of barrier-related prescription decisions.
Insight into 8 Major Myeloma Drugs
Darzalex (daratumumab; Johnson & Johnson)
Empliciti (elotuzumab; BMS/AbbVie)
Farydak (panobinostat; Novartis)
Kyprolis (carfilzomib; Amgen)
Ninarlo (ixazomib; Takeda)
Pomalyst (pomalidomide; Celgene)
Revlimid (lenalidomide; Celgene)
Thalomid (thalidomide; Celgene)
Velcade (bortezomib; Takeda)
Exploring Important Market Access Issues
Market Access Impact: Myeloma explores key issues affecting Myeloma drug manufacturers. You’ll learn:
How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?
How barriers affect your brand:
How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 100 US medical oncologists and haematologists, chosen from the largest community of validated physicians in the world.
All respondents have:
Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with multiple myeloma in total in the last month
We conducted the survey between September 5th and 8th, 2016.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Table of Contents
for Market Access Impact: Myeloma (US) [Report Updated: 01-10-2016]
1. What are the market barriers
2. About this report
3. About the survey
4. Brands included in the survey
5. Executive summary
|Title||Date Published||Price from||More Details|
| Market Access Excellence for Emerging Markets|
IntroductionWhat knowledge, strategies, and resources do you need right now to maximise your company...
|01 May 2015 by FirstWord Pharma||USD $1,866 (normally
| Expanded Access Programs: Opportunities and Challenges for Pharma|
IntroductionExpanded access programmes make available investigational drugs to chronically sick or d...
|20 Apr 2015 by FirstWord Pharma||USD $506 (normally
| Orphan Drug Market Access: Payer Insights on the Present and Future|
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
|14 Oct 2014 by FirstWord Pharma||USD $591 (normally
| Market Access Team Management: driving exceptional performance|
IntroductionThe demands on market access teams are growing rapidly as the specific needs of key stak...
|12 Aug 2014 by FirstWord Pharma||USD $591 (normally
| Oncology Market Access Europe – Payer and Industry Perspectives|
IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
|03 Jul 2014 by FirstWord Pharma||USD $846 (normally
| Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?|
Scope According to analysts at Barclays, oncology continues to attract around one-third of pharma's ...
|28 Apr 2014 by FirstWord Pharma||USD $591 (normally
| The Reality of Market Access in Europe: the role of Health Technology Assessment|
IntroductionFaced with slipping or negligible GDP growth and an economic crisis, Eurozone countries ...
|10 Mar 2014 by FirstWord Pharma||USD $591 (normally
| Market Access for Orphan Drugs: assessing the global landscape|
IntroductionTheir development costs can be high and the market is relative small, yet orphan drugs r...
|01 Dec 2013 by FirstWord Pharma||USD $591 (normally
| Market Access in the EU5 – a comparative overview|
IntroductionThe sustained and challenging economic environment in the EU has impacted – and is impac...
|01 Aug 2013 by FirstWord Pharma||USD $336 (normally
| Market Access: Communicating Value Stories to Payers|
IntroductionThroughout the EU, reimbursement decisions are increasingly decentralised, making the pr...
|01 Apr 2012 by FirstWord Pharma||USD $591 (normally
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.